



JC10 Re PCT/PTO 09 NOV 2005 CT

PATENT #3

Atty Docket: P70484US0

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Confirmation No.: 7511

Hélène LE BUANEC et al.

Serial No.: 10/527,975

Group Art Unit: 1645

Filed: March 15, 2005

Examiner: Unknown

For: STABLE IMMUNOGENIC PRODUCT COMPRISING ANTIGENIC  
HETEROCOMPLEXES

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR 1.97**

**MAIL STOP AMENDMENT**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

As a continuing means of complying with the duty of disclosure under 37 CFR §1.56, and in accordance with 37 CFR §§1.97 and 1.98, Applicant through his undersigned attorney, submits this Information Disclosure Statement for the Examiner's consideration. The patents, publications or other information submitted herewith are listed on the attached Form PTO-1449. In accordance with 37 CFR §1.98(a)(2) only a copy of each foreign patent document and non-patent literature document listed on the attached Form PTO-1449 is submitted herewith.

In accordance with 37 CFR §1.97(b) this Information Disclosure Statement is being submitted before the mailing of the first Office Action on the merits and therefore, no fee is due.

The patents and publications AB, AC and AF - AM listed on Form PTO-1449 were cited in an International Search Report in counterpart International patent application No.

PCT/FR03/02733. A copy of the International Search Report is enclosed.

Documents AA, AD and AE are cited in the instant application on page 3. Document AC is also cited in the instant application on page 2 and document AI on page 21 of the instant application.

It is respectfully requested that the Examiner initial and return a copy of the enclosed Form PTO-1449, and to similarly indicate in the official file wrapper of this patent application that the attached documents have been considered. If the Examiner has any questions or wishes to discuss this application, the Examiner is invited to telephone the undersigned representative at the number set forth below.

Respectfully submitted,

JACOBSON HOLMAN PLLC

Date: 11/9/05

By: 

Allen S. Melser

Registration No. 27,215

**Customer No. 00,136**  
400 Seventh Street, N.W.  
Washington, D.C. 20004  
(202) 638-6666

NOV 09 2005

## Form PTO-1449

## INFORMATION DISCLOSURE STATEMENT

Attorney Docket:	P70484US0
Application No.:	10/527,975
Filing Date:	March 15, 2005
Inventor:	Hélène LE BUANEC et al.
Art Unit:	1645
Examiner:	Unknown

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number	Publication Date	Name of Patentee or Applicant	Relevant Pages, Cols, Lines, Figs.
	AA	US- 5008116	04/16/1991	Cahn	
	AB	US- 6093405	07/25/2000	Zagury et al.	
	AC	US- 6340461	01/22/2002	Terman	
	AD	US- 20020098203	07/25/2002	Gustavsson et al.	

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Country Code + Number	Publication Date	Name of Patentee or Applicant	Relevant Pages, Cols, Lines, Figs.	Translation
	AE	FR 2635532	02/23/1990	Tiollais et al.		Abstract Only
	AF	WO 9101146 A1	02/07/1991	Pillai et al.		N/A
	AG	WO 9627389 A1	09/12/1996	Zagury et al.		Abstract Only
	AH	WO 9957981 A1	11/18/1999	Agus et al.		N/A
	AI	WO 0003732 A1	01/27/2000	Zagury		Abstract Only
	AJ	WO 0211759 A1	02/14/2002	Zagury et al.		Abstract Only
	AK	WO 0222164 A1	03/21/2002	Plebanski		N/A

## NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of author in CAPS; title of article; title of book, magazine, journal etc.; date; page(s); volume/issue number(s); publisher; city and/country where published.
	AL	SHIRAKAWA et al, "VEGF121-specific monoclonal antibodies, hybridomas producing them, and determination of VEGF using the antibodies," Chemical Abstracts Service, 1999, XP00224246.
	AM	KIM et al., "Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUCI-KLH and GD3-KLH conjugate cancer vaccines," Vaccine 18, (2000), pp. 597-603, XP002242468.

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.